Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.61

+3.5%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1614)	9/19/2007 11:18:41 PM
From: Jibacoa	Read Replies (1) of 3722

ANX Was up 8.41% with volume a little ahead of its average. bigcharts.marketwatch.com It was apparently responding to the presentation by its CEO,Evan M. Levine, at the ThinkEquity Partners' Fifth Annual Growth Conference today in San Francisco. On Sep10 it announced that it has received confirmation from the FDA on its NDA for ANX-514. (The FDA has indicated that data from a single study of approximately 28 patients that demonstrated the bioequivalence of ANX-514 and docetaxel is sufficient to support filing an NDA.) Docetaxel which is marketed under the brand name Taxotere had sales of $2.2B in 2006 <g> ANX was able to trim its loss some in the last Q. It reportedly doesn't have significant LTD & the insiders hold >15%. The short ratio was up 20% in the last month & it was about 16x its DAV. The stock seems to have support at the $2.15 level & the R/R doesn't look bad.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next